Mohammed Al-Azzani

Mr. Mohammed Al-Azzani

Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegen-eration, University Medical Center Göttingen, Waldweg 33, 37073 Göttingen, Germany.
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
EVEftychia Vasili
Eftychia Vasili
ADAntonio Dominguez-Meijide
Antonio Dominguez-Meijide
MFManuel Flores-León
Manuel Flores-León
MAMohammed Al-Azzani
Mohammed Al-Azzani
AKAngeliki Kanellidi
Angeliki Kanellidi
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the accumulation of misfolded alpha-synuclein in intraneuronal inclusions known as Lewy bodies and Lewy neurites. Multiple studies strongly implicate the levels of alpha-synuclein as a major risk factor for the onset and progression of Parkinson’s disease. Alpha-synuclein pathology spreads progressively throughout interconnected brain regions but the precise molecular mechanisms underlying the seeding of alpha-synuclein aggregation are still unclear. Here, using stable cell lines expressing alpha-synuclein, we examined the correlation between endogenous alpha-synuclein levels and the seeding propensity by exogenous alpha-synuclein preformed fibrils. We applied biochemical approaches and imaging methods in stable cell lines expressing alpha-synuclein and in primary neurons to determine the impact of alpha-synuclein levels on seeding and aggregation. Our results indicate that the levels of alpha-synuclein define the pattern and severity of aggregation and the extent of p-alpha-synuclein deposition, likely explaining the selective vulnerability of different cell types in synucleinopathies. The elucidation of the cellular processes involved in the pathological aggregation of alpha-synuclein will enable the identification of novel targets and the development of therapeutic strategies for Parkinson’s disease and other synucleinopathies.

1 October 2017 in Physiology & Behavior
Verified
Journal Article
Closed access
KNKhawla Nuseir
Khawla Nuseir
KAKarem H. Alzoubi
Karem H. Alzoubi
AAAhmed Alhusban
Ahmed Alhusban
ABAreej Bawaane
Areej Bawaane
MAMohammed Al-Azzani
Mohammed Al-Azzani
OKOmar F. Khabour
Omar F. Khabour

18 February 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MAMohammed Al-Azzani
Mohammed Al-Azzani
AKAnnekatrin König
Annekatrin König
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Synucleinopathies are a group of neurodegenerative diseases, characterized by the abnormal accumulation of the protein alpha-synuclein (aSyn). aSyn is an intrinsically disordered protein that can adopt different aggregation states, some of which may be associated with disease. Therefore, understanding the transitions between such aggregation states may be essential for deciphering the molecular underpinnings underlying synucleinopathies. Recombinant aSyn is routinely produced and purified from E. coli in many laboratories, and in vitro preparations of aSyn aggregated species became central for modeling neurodegeneration in cell and animal models. Thus, reproducibility and reliability of such studies largely depends on the purity and homogeneity of aSyn preparations across batches and between laboratories. A variety of different methods are in use to produce and purify aSyn, which we review in this commentary. We also show how extraction buffer composition can affect aSyn aggregation, emphasizing the importance of standardizing protocols to ensure reproducibility between different laboratories and studies, which are essential for advancing the field.

8 April 2021 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
KNKhawla Nuseir
Khawla Nuseir
KAKarem H. Alzoubi
Karem H. Alzoubi
AAAhmed Y. Alhusban
Ahmed Y. Alhusban
MAMohammed Al-Azzani
Mohammed Al-Azzani
ABAreej Bawaane
Areej Bawaane
OKOmar F. Khabour
Omar F. Khabour

25 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CBChristof Brücke
Christof Brücke
MAMohammed Al-Azzani
Mohammed Al-Azzani
NRNagendran Ramalingam
Nagendran Ramalingam
MRMaria Ramón
Maria Ramón
RSRita L. Sousa
Rita L. Sousa
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Background: Parkinson’s disease (PD) affects millions of people worldwide, but only 5–10% of patients suffer from a monogenic form of the disease with Mendelian inheritance. SNCA, the gene encoding for the protein alpha-synuclein (aSyn), was the first to be associated with familial forms of PD and, since then, several missense variants and multiplications of the SNCA gene have been established as rare causes of autosomal dominant forms of PD. Aim and methods: A patient carrying aSyn missense mutation and his family members were studied. We present the clinical features, genetic testing - whole exome sequencing (WES), and neuropathological findings. The functional consequences of this aSyn variant were extensively investigated using biochemical, biophysical, and cellular assays. Results: The patient exhibited a complex neurodegenerative disease that included generalized myocloni, bradykinesia, dystonia of the left arm and apraxia. WES identified a novel heterozygous SNCA variant (cDNA 40G>A; protein G14R). Neuropathological examination showed extensive atypical aSyn pathology with frontotemporal lobar degeneration (FTLD) and nigral degeneration pattern with abundant ring-like neuronal inclusions, and few oligodendroglial inclusions. Sanger sequencing confirmed the SNCA variant in the healthy, elderly parent of the patient patient suggesting incomplete penetrance. NMR studies suggest that the G14R mutation induces a local structural alteration in aSyn, and lower thioflavin T binding in in vitro fibrillization assays. Interestingly, the G14R aSyn fibers display different fibrillar morphologies as revealed by cryo-electron microscopy. Cellular studies of the G14R variant revealed increased inclusion formation, enhanced membrane association, and impaired dynamic reversibility of serine-129 phosphorylation. Summary: The atypical neuropathological features observed, which are reminiscent of those observed for the G51D aSyn variant, suggest a causal role of the SNCA variant with a distinct clinical and pathological phenotype, which is further supported by the properties of the mutant aSyn, compatible with the strain hypothesis of proteinopathies.

4 September 2025 in Movement Disorders
Verified
Journal Article
Open access
MAMohammed Al-Azzani
Mohammed Al-Azzani
SWSandrina Weber
Sandrina Weber
NRNagendran Ramalingam
Nagendran Ramalingam
MRMaria Ramón
Maria Ramón
LSLiana Shvachiy
Liana Shvachiy
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Background: Parkinson's disease (PD) is a complex multifactorial disorder with a genetic component in about 15% of cases. Multiplications and point mutations in SNCA gene, encoding α‐synuclein (aSyn), are linked to rare familial forms of PD. Objective: Our goal was to assess the clinical presentation and the biological effects of a novel K58N aSyn mutation identified in a patient with PD. Methods: We describe the clinical presentation associated with the novel mutation, together with genetic testing through whole exome sequencing (WES). Furthermore, we conducted extensive biophysical and cellular assays to assess the functional consequences of this novel variant. Results: The patient exhibited typical features of sporadic PD with early onset and a benign disease course. WES showed a novel heterozygous missense variant in SNCA (NM_000345.4, c.174G>C; p.K58N). A positive family history of PD was evident, because both a parent and a grandparent had been diagnosed with PD but were deceased. The patient underwent deep brain stimulation surgery 13 years postdiagnosis, showing stable, long‐term improvements in motor symptoms. Biophysical studies demonstrated K58N substitution causes local structural effects, disrupts membrane binding, and enhances aSyn in vitro aggregation. In cellular systems, K58N aSyn produces fewer inclusions per cell and does not form condensates. The variant increases aSyn cytoplasmic distribution and displays aberrant activity‐dependent dynamic serine‐129 phosphorylation. Conclusions: The clinical presentation associated with the novel K58N aSyn mutation suggests a relatively benign PD course consistent with the phenotypic spectrum of idiopathic PD. Overall, our molecular studies provide novel insight into the biology and pathobiology of aSyn. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.